Latest Insider Transactions at Novo Cure LTD (NVCR)
This section provides a real-time view of insider transactions for Novo Cure LTD (NVCR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NovoCure Ltd to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NovoCure Ltd's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 04
2025
|
Kristin Stafford |
BUY
Grant, award, or other acquisition
|
Direct |
11,215
+44.01%
|
-
|
|
Jun 04
2025
|
Gabriel Leung |
BUY
Grant, award, or other acquisition
|
Direct |
11,215
+10.82%
|
-
|
|
Jun 04
2025
|
Timothy J Scannell |
BUY
Grant, award, or other acquisition
|
Direct |
11,215
+39.42%
|
-
|
|
Jun 04
2025
|
Allyson J Ocean |
BUY
Grant, award, or other acquisition
|
Direct |
11,215
+44.01%
|
-
|
|
Jun 04
2025
|
Jeryl L Hilleman |
BUY
Grant, award, or other acquisition
|
Direct |
11,215
+40.02%
|
-
|
|
Jun 04
2025
|
Frank X Leonard EVP, Pres., Novocure Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
179,426
+34.03%
|
-
|
|
Jun 04
2025
|
W Anthony Vernon |
BUY
Grant, award, or other acquisition
|
Direct |
11,215
+5.89%
|
-
|
|
Jun 04
2025
|
David Hung |
BUY
Grant, award, or other acquisition
|
Direct |
11,215
+32.39%
|
-
|
|
Jun 03
2025
|
Gabriel Leung |
SELL
Open market or private sale
|
Direct |
999
-1.21%
|
$16,983
$17.31 P/Share
|
|
Jun 03
2025
|
Kristin Stafford |
SELL
Open market or private sale
|
Direct |
999
-24.65%
|
$16,983
$17.28 P/Share
|
|
Jun 03
2025
|
Timothy J Scannell |
SELL
Open market or private sale
|
Direct |
999
-14.24%
|
$16,983
$17.32 P/Share
|
|
Jun 03
2025
|
Martin J. Madden |
SELL
Open market or private sale
|
Direct |
999
-5.08%
|
$16,983
$17.19 P/Share
|
|
Jun 03
2025
|
Allyson J Ocean |
SELL
Open market or private sale
|
Direct |
999
-24.65%
|
$16,983
$17.29 P/Share
|
|
Jun 03
2025
|
Jeryl L Hilleman |
SELL
Open market or private sale
|
Direct |
999
-15.16%
|
$16,983
$17.26 P/Share
|
|
Jun 03
2025
|
David Hung |
SELL
Open market or private sale
|
Direct |
999
-7.57%
|
$16,983
$17.3 P/Share
|
|
Jun 03
2025
|
W Anthony Vernon |
SELL
Open market or private sale
|
Direct |
999
-0.59%
|
$16,983
$17.35 P/Share
|
|
Jun 02
2025
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
30,196
-5.26%
|
$543,528
$18.07 P/Share
|
|
May 03
2025
|
Mukund Paravasthu Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
592
-0.7%
|
$10,064
$17.91 P/Share
|
|
Mar 04
2025
|
Ashley Cordova Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
151,181
+29.86%
|
$2,721,258
$18.19 P/Share
|
|
Mar 04
2025
|
Mukund Paravasthu Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,975
+39.52%
|
$989,550
$18.19 P/Share
|
|
Mar 04
2025
|
Frank X Leonard EVP, Pres., Novocure Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
54,975
+21.68%
|
$989,550
$18.19 P/Share
|
|
Mar 04
2025
|
Uri Weinberg Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,975
+19.9%
|
$989,550
$18.19 P/Share
|
|
Mar 04
2025
|
Michal Nath Puri Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,975
+25.14%
|
$989,550
$18.19 P/Share
|
|
Mar 04
2025
|
Barak Ben Arye General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
54,975
+24.04%
|
$989,550
$18.19 P/Share
|
|
Mar 04
2025
|
Nicolas Leupin Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,975
+34.34%
|
$989,550
$18.19 P/Share
|
|
Mar 04
2025
|
Christoph Brackmann Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,975
+31.21%
|
$989,550
$18.19 P/Share
|
|
Mar 03
2025
|
Mukund Paravasthu Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
250
-0.85%
|
$4,500
$18.54 P/Share
|
|
Mar 03
2025
|
Ashley Cordova Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,053
-1.0%
|
$36,954
$18.54 P/Share
|
|
Mar 03
2025
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
2,527
-1.73%
|
$45,486
$18.54 P/Share
|
|
Mar 03
2025
|
Uri Weinberg Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
268
-0.16%
|
$4,824
$18.92 P/Share
|
|
Feb 28
2025
|
Mukund Paravasthu Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
368
-1.24%
|
$6,624
$18.28 P/Share
|
|
Feb 28
2025
|
Ashley Cordova Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,341
-1.12%
|
$42,138
$18.28 P/Share
|
|
Feb 28
2025
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
2,770
-1.86%
|
$49,860
$18.28 P/Share
|
|
Feb 28
2025
|
Uri Weinberg Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
4,637
-1.36%
|
$83,466
$18.55 P/Share
|
|
Feb 27
2025
|
Mukund Paravasthu Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,646
-2.64%
|
$32,920
$20.24 P/Share
|
|
Feb 27
2025
|
Ashley Cordova Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,153
-2.56%
|
$223,060
$20.24 P/Share
|
|
Feb 27
2025
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
12,266
-3.85%
|
$245,320
$20.24 P/Share
|
|
Feb 27
2025
|
Michal Nath Puri Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
1,387
-0.63%
|
$27,740
$20.24 P/Share
|
|
Feb 27
2025
|
Nicolas Leupin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
991
-0.97%
|
$19,820
$20.24 P/Share
|
|
Jan 11
2025
|
Mukund Paravasthu Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,160
-6.43%
|
$56,160
$26.81 P/Share
|
|
Jan 01
2025
|
Asaf Danziger |
BUY
Grant, award, or other acquisition
|
Direct |
400,000
+49.04%
|
-
|
|
Dec 31
2024
|
Asaf Danziger |
BUY
Grant, award, or other acquisition
|
Direct |
412
+2.57%
|
$5,768
$14.75 P/Share
|
|
Dec 31
2024
|
Ashley Cordova Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
373
+0.17%
|
$5,222
$14.75 P/Share
|
|
Dec 31
2024
|
Barak Ben Arye General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
669
+0.56%
|
$9,366
$14.75 P/Share
|
|
Nov 04
2024
|
Mukund Paravasthu Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,138
+47.29%
|
-
|
|
Nov 02
2024
|
Mukund Paravasthu Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
44
-1.26%
|
$704
$16.69 P/Share
|
|
Nov 01
2024
|
Mukund Paravasthu Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
160
-4.37%
|
$2,400
$15.88 P/Share
|
|
Nov 01
2024
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
598
-0.37%
|
$8,970
$15.94 P/Share
|
|
Oct 31
2024
|
Michal Nath Puri Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
810
-0.73%
|
$12,150
$15.79 P/Share
|
|
Aug 02
2024
|
Ashley Cordova Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
688
-0.31%
|
$13,760
$20.14 P/Share
|